Literature DB >> 10548867

Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV.

W C Holmes1, J A Shea.   

Abstract

OBJECTIVES: Reduce the number of HIV/AIDS-Targeted Quality of Life (HAT-QoL) items, assess psychometric performance of the shortened HAT-QoL, and compare psychometric performance of HAT-QoL to that of Medical Outcomes study HIV Health Survey (MOS-HIV). DESIGN/
SUBJECTS: Convenience sample of 215 cross-sectionally studied seropositive individuals.
METHODS: Subjects completed the HAT-QoL, MOS-HIV, and sociodemographic and disease-specific questions. HAT-QoL and MOS-HIV responses were entered, separately, into principal components analysis (PCA). Results from PCA, internal consistency and correlation assessments were used to aid the item removal process. Dimension characteristics (e.g., score distributions, internal consistency, scaling success rates, intercorrelations, construct validity) were evaluated.
RESULTS: PCA of subjects' (80% male; 45% white; 62% gay/bisexual) responses revealed nine previously identified HAT-QoL dimensions. The measure was shortened by removing 12 items. Two HAT-QoL dimensions (HIV mastery and provider trust) had ceiling effects. All internal consistency coefficients were > 0.80, except those for sexual function (0.57) and medication concerns (0.57). HAT-QoL scaling success rates were > 90% for 7 of 9 dimensions, and a majority of dimensions showed minimal to low intercorrelations. Validity assessments indicated consistent, expected relationships (p < or = 0.05) for all dimensions except the medication concerns and provider trust dimensions. PCA indicated five MOS-HIV factors. Six of the 11 previously defined MOS-HIV dimensions--physical, role, social, and cognitive function, pain, and health transition--had substantial ceiling effects. MOS-HIV scaling success rates were > 90% for only 2 out of 8 evaluable dimensions; three dimensions had very low (40-73%) scaling success rates. Most MOS-HIV dimensions were moderately-to-highly intercorrelated. Validity assessments indicated consistent, expected relationships for all MOS-HIV dimensions.
CONCLUSIONS: Six dimensions of the shortened HAT-QoL instrument (overall function, disclosure worries, health worries, financial worries, HIV mastery, and life satisfaction) exhibited good psychometric properties, including limited ceiling effects, low dimension intercorrelations, high internal consistency, and evidence for construct validity. All multi-item MOS-HIV dimensions had high internal consistency and all dimensions revealed consistent evidence for construct validity.

Entities:  

Mesh:

Year:  1999        PMID: 10548867     DOI: 10.1023/a:1008931006866

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  27 in total

1.  Reliability and validity of self-report CD4 counts-in persons hospitalized with HIV disease.

Authors:  W E Cunningham; H M Rana; M F Shapiro; R D Hays
Journal:  J Clin Epidemiol       Date:  1997-07       Impact factor: 6.437

2.  A new readability yardstick.

Authors:  R FLESCH
Journal:  J Appl Psychol       Date:  1948-06

3.  A modular approach to quality-of-life assessment in cancer clinical trials.

Authors:  N K Aaronson; M Bullinger; S Ahmedzai
Journal:  Recent Results Cancer Res       Date:  1988

4.  Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1987-08-14       Impact factor: 17.586

5.  Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals.

Authors:  W C Holmes; J A Shea
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

6.  Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV Overview of Problems--Evaluation System (HOPES).

Authors:  P A Ganz; C A Coscarelli Schag; B Kahn; L Petersen; K Hirji
Journal:  Qual Life Res       Date:  1993-04       Impact factor: 4.147

7.  Health-related quality of life in persons with acquired immune deficiency syndrome.

Authors:  P D Cleary; F J Fowler; J Weissman; M P Massagli; I Wilson; G R Seage; C Gatsonis; A Epstein
Journal:  Med Care       Date:  1993-07       Impact factor: 2.983

Review 8.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

9.  A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity.

Authors:  S A Bozzette; R D Hays; S H Berry; D E Kanouse
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

10.  Derivation and properties of a brief health status assessment instrument for use in HIV disease.

Authors:  S A Bozzette; R D Hays; S H Berry; D E Kanouse; A W Wu
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-03-01
View more
  27 in total

1.  Validation of the medical outcomes study HIV (MOS-HIV) health survey among HIV-infected patients in Taiwan.

Authors:  Ping-Chuan Hsiung; Chi-Tai Fang; Keng-Lin Lee; Wang-Huei Sheng; Chia-Yun Wu; Jung-Der Wang; Grace Yao
Journal:  Qual Life Res       Date:  2010-08-29       Impact factor: 4.147

2.  Validation of a Chinese version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) among Chinese people living with HIV/AIDS in Hong Kong.

Authors:  Joseph T F Lau; Hi Yi Tsui; Li C K Patrick; Chung W Y Rita; Alexander Molassiotis
Journal:  Qual Life Res       Date:  2006-08       Impact factor: 4.147

Review 3.  A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.

Authors:  Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Sleep quality and health-related quality of life in HIV-infected African-American women of childbearing age.

Authors:  Kenneth D Phillips; Richard L Sowell; Mary Boyd; Wesley D Dudgeon; Gregory A Hand
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

5.  Exploring the contribution of general self-efficacy to the use of self-care symptom management strategies by people living with HIV infection.

Authors:  Inge B Corless; Dean Wantland; Kenn M Kirksey; Patrice K Nicholas; Sarie Human; John Arudo; Maria Rosa; Yvette Cuca; Sue Willard; Mary Jane Hamilton; Carmen Portillo; Elizabeth Sefcik; Linda Robinson; Cathy Bain; Shanaz Moezzi; Mary Maryland; Emily Huang; William L Holzemer
Journal:  AIDS Patient Care STDS       Date:  2012-05-21       Impact factor: 5.078

6.  Reliability and validity of two HIV/AIDS-specific quality of life instruments adapted for use in HIV-positive Zimbabweans.

Authors:  Tonya N Taylor; Curtis Dolezal; Susan Tross; William C Holmes
Journal:  AIDS Care       Date:  2009-05

7.  Quality of life of HIV-infected patients: psychometric properties and validation of the German version of the MQOL-HIV.

Authors:  G Kemmler; B Schmied; A Shetty-Lee; R Zangerle; H Hinterhuber; G Schüssler; B Mumelter
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

8.  Validity and reliability of the Italian translation of the MOS-HIV health survey in persons with AIDS.

Authors:  Patrizia Schifano; Piero Borgia; Albert W Wu; Teresa Spadea; Giuseppe Milanese; Carlo A Perucci
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  The impact of stressful life events, symptom status, and adherence concerns on quality of life in people living with HIV.

Authors:  Inge B Corless; Joachim Voss; A J Guarino; Dean Wantland; William Holzemer; Mary Jane Hamilton; Elizabeth Sefcik; Suzanne Willard; Kenn Kirksey; Carmen Portillo; Marta Rivero Mendez; Maria E Rosa; Patrice K Nicholas; Sarie Human; Mary Maryland; Shahnaz Moezzi; Linda Robinson; Yvette Cuca
Journal:  J Assoc Nurses AIDS Care       Date:  2013-03-07       Impact factor: 1.354

Review 10.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.